We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Moderna Starts Dosing of Adolescents in Phase 2/3 COVID-19 Vaccine Trial
Moderna Starts Dosing of Adolescents in Phase 2/3 COVID-19 Vaccine Trial
Moderna has begun dosing adolescents in a phase 2/3 trial evaluating messenger RNA-based vaccine candidate mRNA-1273 and plans to enroll 3,000 U.S. participants aged 12 to 17.